News

The Manila Times12m
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...
The Manila Times12m
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Purple Biotech Ltd. ('Purple Biotech' or 'the Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing ...
CNBCTV1837m
Syngene Q1 Results: Numbers better than analyst expectations, FY26 guidance maintained
Syngene's margins narrowed on a sequential basis. Apart from margins, Syngene's revenue and EBITDA are also lower by 14.1% ...